FCB lands two DTC accounts

Share this article:
FCB was awarded the DTC advertising for Hoffman-LaRoche's two drugs, Pegasys and Copegus, that treat hepatitis C. Annual media spending for upcoming campaigns could exceed $30 million, sources said.
The agency, which is a unit of the Interpublic Group, pitched against three other undisclosed agencies.
Pegasys and Copegus were approved by the FDA two years ago, but this marks the first DTC campaign for both. The FDA has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for the combination therapy of Pegasys in combination with Copegus for the treatment of hepatitis C in patients who are also infected with HIV. Roche submitted this file with the FDA in August 2004.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.